Drew A Westmoreland1, Jesse L Goldshear2, Adam W Carrico3, Christian Grov4. 1. CUNY Institute for Implementation Science in Population Health, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA. 2. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. 3. Department of Public Health Sciences, University of Miami, Miami, FL, USA. 4. CUNY Institute for Implementation Science in Population Health, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA; Department of Community Health and Social Sciences, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA. Electronic address: cgrov@sph.cuny.edu.
Abstract
INTRODUCTION: Prescription stimulants and methamphetamine have similarities in chemical structure and impact on biological functioning. However, there is limited literature on prescription stimulant misuse among sexual and gender minorities as well as how prescription misuse may impact later methamphetamine use. METHODS: We used data collected from a HIV prevention cohort to describe (e.g., frequencies, percentages) prescription stimulant use/misuse and methamphetamine use at baseline and 12-month follow-up (n = 4857). We then used multivariable logistic regression models to determine the impact of baseline prescription stimulant misuse and methamphetamine use on 12-month prescription stimulant misuse and methamphetamine use. RESULTS: At baseline, 10.2 % of participants misused prescription stimulants and 12 % of participants used methamphetamine in the past 3 months, while at 12-month follow-up 11.6 % of participants misused prescription stimulants and 11.2 % of participants used methamphetamine in the past 3 months. Multivariable regression analyses indicated that participants who misused prescription stimulants (in the absence of methamphetamine) at baseline had 2.51 (95 % CI: 1.44-3.59, ref. no stimulant or methamphetamine use) times the odds of using methamphetamine at 12-month follow-up. DISCUSSION: Findings suggest that prescription stimulant use is a risk factor for continued meth use. Therefore, earlier and targeted public health interventions could reduce methamphetamine use by disrupting the progression from prescription stimulant misuse to methamphetamine use through early screening and interventions for prescription stimulant misuse.
INTRODUCTION: Prescription stimulants and methamphetamine have similarities in chemical structure and impact on biological functioning. However, there is limited literature on prescription stimulant misuse among sexual and gender minorities as well as how prescription misuse may impact later methamphetamine use. METHODS: We used data collected from a HIV prevention cohort to describe (e.g., frequencies, percentages) prescription stimulant use/misuse and methamphetamine use at baseline and 12-month follow-up (n = 4857). We then used multivariable logistic regression models to determine the impact of baseline prescription stimulant misuse and methamphetamine use on 12-month prescription stimulant misuse and methamphetamine use. RESULTS: At baseline, 10.2 % of participants misused prescription stimulants and 12 % of participants used methamphetamine in the past 3 months, while at 12-month follow-up 11.6 % of participants misused prescription stimulants and 11.2 % of participants used methamphetamine in the past 3 months. Multivariable regression analyses indicated that participants who misused prescription stimulants (in the absence of methamphetamine) at baseline had 2.51 (95 % CI: 1.44-3.59, ref. no stimulant or methamphetamine use) times the odds of using methamphetamine at 12-month follow-up. DISCUSSION: Findings suggest that prescription stimulant use is a risk factor for continued meth use. Therefore, earlier and targeted public health interventions could reduce methamphetamine use by disrupting the progression from prescription stimulant misuse to methamphetamine use through early screening and interventions for prescription stimulant misuse.
Authors: Sean Esteban McCabe; Christian J Teter; Carol J Boyd; Timothy E Wilens; Ty S Schepis Journal: J Clin Psychiatry Date: 2018 Mar/Apr Impact factor: 4.384
Authors: Aleksandar Kecojevic; Carolyn F Wong; Heather L Corliss; Stephen E Lankenau Journal: Drug Alcohol Depend Date: 2015-03-06 Impact factor: 4.492
Authors: Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Emma S Rathkey; Alison McCallum Journal: Exp Clin Psychopharmacol Date: 2016-10 Impact factor: 3.157
Authors: Christine M Khosropour; Brent A Johnson; Alexandra V Ricca; Patrick S Sullivan Journal: J Med Internet Res Date: 2013-08-27 Impact factor: 5.428